Takeshita H, Furukawa M, Fujieda S, Shoujaku H, Ookura T, Sakaguchi M, Ito H, Mineta H, Harada T, Matsuura H, Saito H
Department of Otolaryngology, School of Medicine, Kanazawa University, Ishikawa, Japan.
Auris Nasus Larynx. 1999 Jul;26(3):277-86. doi: 10.1016/s0385-8146(98)00080-7.
Although patient death due to nasopharyngeal carcinoma (NPC) is increasing, few epidemiological analyses of NPC in Japan have been conducted since Sawaki's report in 1979. To determine the current incidence of NPC in Japan we examined NPC case in the Chubu area from 1986 to 1995. The leaders and reporting representatives of all otorhinolaryngological groups in the area were asked for their support of this epidemiological research. A total of 607 cases (445 male and 162 female NPC patients) were analyzed epidemiologically, histologically, serologically and clinically in this study. The incidence of NPC gradually increased with age. The mean age of the patients was 54.1 years. The age-standardized annual incidence in the Chubu region was 0.28 per 10(5) persons per year. The incidence in prefectures bordering Japan Sea (0.36) was significantly higher than that of prefectures facing the Pacific Ocean (0.21, P<0.05). On the basis of World Health Organization (WHO) histological criteria, 12%) of the cases were classified as WHO I, 54% as WHO II and 34% as WHO III. As for tumor origin, in 58% of the cases it originated posterosuperiorly, in 32% laterally and in 1% inferiorly. Tumor staging showed 4% to belong to stage I, 9% to stage II, 15% to stage III and 72% to stage IV. The positive rates of serum titers of the antibodies to Epstein Barr virus
尽管鼻咽癌(NPC)导致的患者死亡人数在增加,但自1979年泽aki的报告以来,日本很少对鼻咽癌进行流行病学分析。为了确定日本目前鼻咽癌的发病率,我们调查了1986年至1995年中部地区的鼻咽癌病例。该地区所有耳鼻喉科团体的负责人和报告代表被请求支持这项流行病学研究。本研究对总共607例病例(445例男性和162例女性鼻咽癌患者)进行了流行病学、组织学、血清学和临床分析。鼻咽癌的发病率随年龄逐渐增加。患者的平均年龄为54.1岁。中部地区年龄标准化的年发病率为每10万人每年0.28例。与日本海接壤的县的发病率(0.36)明显高于面向太平洋的县的发病率(0.21,P<0.05)。根据世界卫生组织(WHO)的组织学标准,12%的病例被归类为WHO I型,54%为WHO II型,34%为WHO III型。至于肿瘤起源,58%的病例起源于后上方,32%起源于侧面,1%起源于下方。肿瘤分期显示4%属于I期,9%属于II期,15%属于III期,72%属于IV期。爱泼斯坦-巴尔病毒抗体血清滴度的阳性率